A routine complete blood count, one of the cheapest and most widely ordered tests in medicine, may carry far more information about thyroid disease than clinicians have traditionally assumed. A new retrospective cohort study published in BMC Endocrine Disorders suggests that four simple indices calculated from the hemogram—the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV)—follow strikingly different trajectories over a full year of follow-up depending on which form of thyrotoxicosis a patient has. The finding, drawn from 201 adults treated across four diagnostic categories, offers a fresh longitudinal view of how systemic inflammation behaves as overactive thyroid conditions are brought under control.
Thyrotoxicosis, the clinical state produced by excess circulating thyroid hormone, is not a single disease but a family of disorders with fundamentally different biological mechanisms. Subacute thyroiditis (SAT) is a painful, virus-associated inflammatory destruction of thyroid tissue that releases stored hormone in a burst. Graves’ disease is an autoimmune condition in which antibodies chronically stimulate the thyroid. Toxic multinodular goiter (TMNG) and toxic adenoma arise from autonomously functioning nodules that secrete hormone without a significant inflammatory component. Because these conditions differ so sharply in their underlying biology, researchers have long suspected that markers of systemic inflammation might behave differently across them—but longitudinal data tracking those markers over months of treatment have been scarce.
The study, conducted by Nejla Küçük of Mugla Training and Research Hospital and Hülya Coşkun of Karadeniz Technical University in Türkiye, set out to fill that gap. The researchers assembled a cohort of 201 adults distributed across the four major etiologies of thyrotoxicosis and measured their hemogram-derived inflammatory indices at baseline and then at one, three, six, and twelve months of follow-up. Because only six patients had toxic adenoma, that subgroup was retained for descriptive analysis only, and the primary longitudinal modeling focused on 195 patients with SAT, Graves’ disease, or TMNG. The retrospective design meant the ethics committee waived individual informed consent, and the work was carried out in accordance with the Declaration of Helsinki.
Methodologically, the team took care to handle the statistical quirks of these ratios. NLR and PLR were natural-log transformed, MLR was cube-root transformed, and MPV was analyzed on its original scale, choices that help satisfy the distributional assumptions of the models. They then employed age- and sex-adjusted linear mixed-effects models, a technique well suited to repeated-measures data because it uses all available observations without requiring imputation of missing follow-up values. The key test was the disease-by-time interaction: a significant result would indicate that the inflammatory indices did not simply rise or fall uniformly, but changed in ways that depended on the underlying diagnosis.
That is precisely what the data showed. The disease-by-time interactions were statistically significant for all four indices: NLR (F(8, 292.433) = 8.080, p < 0.001), MLR (F(8, 263.220) = 3.298, p = 0.001), PLR (F(8, 320.648) = 11.496, p < 0.001), and MPV (F(8, 329.878) = 2.616, p = 0.009). In plain terms, the trajectory of each inflammatory marker over the twelve months depended strongly on which form of thyrotoxicosis the patient had—a pattern that mirrors the very different immunological signatures of the diseases themselves.
The most dramatic changes appeared in subacute thyroiditis, the one etiology in the cohort driven by overt thyroid inflammation. In SAT patients, NLR and PLR declined markedly after treatment began and remained lower throughout the entire follow-up period, while MLR also decreased significantly. This makes biological sense: as the inflammatory destruction of the thyroid resolves, the neutrophil-driven and platelet-activated inflammatory state recedes, and the ratios that capture that state fall back toward baseline. Interestingly, MPV—a measure of the average size of platelets, often interpreted as a marker of platelet activation—moved in the opposite direction, increasing modestly in SAT patients particularly at the six- and twelve-month marks.
Graves’ disease told a more restrained story. As an autoimmune disorder, it involves chronic lymphocyte activation rather than acute tissue destruction, and the hemogram indices reflected that: longitudinal changes were present but more limited than in SAT. Toxic multinodular goiter, which involves essentially no systemic inflammation, showed no clear overall temporal change in the inflammatory ratios at all. The gradient across the three conditions—from pronounced change in SAT, to limited change in Graves’ disease, to essentially none in TMNG—tracks neatly with the degree of inflammatory activity each condition is known to produce, lending the findings a satisfying internal coherence.
What makes this study notable in the broader landscape of inflammation research is its longitudinal design. Most prior work on NLR, PLR, MLR, and MPV in thyroid and systemic inflammatory disorders has been cross-sectional, capturing a single snapshot and leaving open whether the indices merely mark a state or genuinely track disease activity over time. By following patients across five time points over a year, the Turkish team demonstrated that these cheap, routinely available measures are biologically responsive: they move as the disease process moves. That responsiveness is a prerequisite for any future role in monitoring, even if it does not by itself establish clinical usefulness.
The authors are careful on that point, and their caution deserves emphasis. The findings support the biological responsiveness of hemogram-derived inflammatory indices to inflammatory activity, but they do not establish incremental clinical utility over established inflammatory markers such as C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR). CRP and ESR remain the workhorses for assessing inflammatory activity in conditions like subacute thyroiditis, and the new study does not claim that the blood-count ratios outperform them. Whether NLR, MLR, PLR, or MPV add diagnostic, prognostic, or monitoring value beyond these established markers is a question the retrospective design cannot answer, and the authors explicitly call for prospective studies to clarify their independent worth.
Still, the study adds a meaningful piece to a growing body of literature on hemogram-derived indices, which have been investigated across cardiovascular disease, oncology, and numerous inflammatory conditions precisely because they cost nothing extra—they are derived from a test virtually every patient already receives. If future prospective work confirms that these ratios can help distinguish inflammatory from non-inflammatory causes of thyrotoxicosis, or track recovery in subacute thyroiditis without additional blood draws, the humble complete blood count could become an even more informative window into thyroid disease. For now, the message is one of biological insight rather than immediate practice change: the fingerprints of inflammation written in a routine blood count differ profoundly across the causes of thyrotoxicosis, and they fade, persist, or stay silent in ways that faithfully mirror each disease’s underlying nature.
Subject of Research: Longitudinal changes in hemogram-derived inflammatory markers across different etiologies of thyrotoxicosis
Article Title: “Changes in hemogram-derived inflammatory markers before and after treatment in different etiologies of thyrotoxicosis: a retrospective cohort study”
Article References: Küçük, N., & Coşkun, H. (2026). “Changes in hemogram-derived inflammatory markers before and after treatment in different etiologies of thyrotoxicosis: a retrospective cohort study”. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02653-9
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02653-9
Keywords: thyrotoxicosis, subacute thyroiditis, Graves' disease, toxic multinodular goiter, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, inflammatory markers, hemogram, endocrinology, retrospective cohort study
News Source: Ophelia Keating. (October 13, 2026). Simple Blood Count Ratios Reveal Hidden Inflammation Patterns in Thyrotoxicosis. Scienmag.
